<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483560</url>
  </required_header>
  <id_info>
    <org_study_id>GN10DI406</org_study_id>
    <secondary_id>2011-000300-18</secondary_id>
    <nct_id>NCT01483560</nct_id>
  </id_info>
  <brief_title>REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)</brief_title>
  <acronym>REMOVAL</acronym>
  <official_title>Phase 3 Study of Metformin in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Serono S.A., Geneva</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Itamar-Medical, Israel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is conducted in the UK, Australia, Canada, Denmark and the Netherlands. The aim is
      to test whether 3 years treatment with metformin added to titrated insulin therapy (towards
      target HbA1c7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid
      IMT, in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for
      cardiovascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 18, 2017</completion_date>
  <primary_completion_date type="Actual">March 19, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in averaged mean far wall common carotid artery IMT</measure>
    <time_frame>0, 12 months, 24 months, 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in albuminuria &amp; estimated glomerular filtration rate</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Number of participants developing new microalbuminuria; change in absolute concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in retinopathy stage</measure>
    <time_frame>Baseline, Year 3</time_frame>
    <description>ETDRS grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin dose</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function</measure>
    <time_frame>Baseline, Year 1, Year 3</time_frame>
    <description>RHI units</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>3 years treatment duration</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 years duration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes for five years or more*

          -  Age 40 years or above

          -  7.0 =&lt; HbA1c &lt;10.0% (53 - 86 mmol/mol)

        AND 3 or more of the following ten CVD risk factors:

          -  BMI &gt;27 kg/m^2

          -  Current HbA1c &gt;8.0% (64 mmol/mol)

          -  Known CVD/peripheral vascular disease

          -  Current smoker

          -  Estimated glomerular filtration rate &lt;90 ml/min per 1.73 m^3

          -  Confirmed micro- or macroalbuminuria [according to local assays and reference ranges]

          -  Hypertension (BP &gt;=140/90mmHg or established on antihypertensive treatment)

          -  Dyslipidaemia [total cholesterol &gt;=5.0 mmol/L (200 mg/dL);OR HDL cholesterol &lt;1.20
             mmol/L (46mg/dL) [MEN]; OR &lt;1.30 mmol/L (50 mg/dL) [WOMEN]; or triglycerides &gt;=1.7
             mmol/L (150mg/dL); or established on lipid-lowering treatment)]

          -  Strong family history of CVD (at least one parent, biological aunt/ uncle, or sibling
             with myocardial infarction or stroke aged &lt;60 years)

          -  Duration of diabetes &gt; 20 years

        Exclusion Criteria:

          -  eGFR &lt; 45 ml/min/1.73m2

          -  woman of childbearing age not on effective contraception

          -  Pregnancy and/or lactation

          -  Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three
             months

          -  NYHA stage 3 or 4 heart failure

          -  Significant hypoglycaemia unawareness

          -  Impaired cognitive function/ unable to give informed consent

          -  Previous carotid surgery/ inability to capture adequate carotid images

          -  Estimated glomerular filtration &lt; 45ml/min/1.73m^2 (MDRD)

          -  Gastroparesis

          -  History of lactic acidosis

          -  Other contraindications to metformin (hepatic impairment, known hypersensitivity to
             metformin, acute illness such as dehydration, severe infection, shock, acute cardiac
             failure or suspected tissue hypoxia)

          -  Any coexistent life threatening condition including prior diagnosis of cancer within
             two years

          -  History of alcohol problem or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Petrie, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Colhoun, Prof</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Albert Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Health Care</name>
      <address>
        <city>Ontario</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Riverside Campus</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Centre</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Support Unit, Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital North Durham</name>
      <address>
        <city>Durham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Western Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stobhill Hospital, Diabetes Clinic</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael White Diabetes Centre, Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Sciences Centre, University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle NIHR Clinical Research Facility, Royal Victoria Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Clinical Research Centre, Plymouth</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Glasgow</investigator_affiliation>
    <investigator_full_name>Prof John Petrie</investigator_full_name>
    <investigator_title>Clinical Professor in Diabetic Medicine</investigator_title>
  </responsible_party>
  <keyword>REMOVAL</keyword>
  <keyword>metformin</keyword>
  <keyword>carotid IMT</keyword>
  <keyword>LDL Cholesterol</keyword>
  <keyword>endothelial function</keyword>
  <keyword>retinopathy</keyword>
  <keyword>HbA1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Site specific participant data will be made available to the site PIs later in 2017, after the main publications.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

